Updates

Categories
  1. TheSocialMedwork commitment during the COVID-19 outbreak

    Here are some frequently asked questions and answers that touch on important COVID-19 related updates.

    Read more »
  2. Promising new data analysis for Alzheimer’s disease treatment

    New analysis of Biogen’s aducanumab shows reduction in clinical decline in Alzheimer’s disease.

    Xray of human brain

    Read more »
  3. MN-166 (ibudilast) to enter phase III clinical trials for progressive MS

    MN-166 (ibudilast) will be part of the Phase III clinical trial on progressive multiple sclerosis subjects with secondary progressive MS without relapses. 

    pipette samples

    Read more »
  4. Phase 2 study: Ibudilast's effects in progressive MS

    Phase 2 clinical trial shows that ibudilast is linked to a 48% slowing in the progression of brain atrophy compared to placebo for patients with progressive MS.

    red mri brain scan

    Read more »
  5. New cancer medicine targets tumour biomarkers anywhere in the body

    The new site-agnostic cancer medicine, Vitrakvi (larotrectinib), gets accelerated approval from the U.S. Food and Drug Administration (FDA).

    US flag thumbs up gesture

    Read more »
  6. Lung cancer medicine receives positive opinion in the EU

    CHMP's assessment supports EMA's approval of non-small cell lung cancer (NSCLC) medicine, Vizimpro (dacomitinib).

    EU approval OK hand gesture

    Read more »
  7. Cancer medicine, Lartruvo (olaratumab), does not prolong life

    After failing to show a clear benefit over chemotherapy on its own, both the FDA and EMA do not recommend Lartruvo (olaratumab) for use in combination with chemotherapy for new STS patients.

    old bench

    Read more »
  8. Truxima (rituximab) gains FDA approval as the first biosimilar for Non-Hodgkin's Lymphoma

    A new biosimilar, Truxima (rituximab), shows comparable results to the reference medicine, Rituxan (rituximab), and takes FDA one step further toward expanding patient access to medicines.

    approved stamp with stars

    Read more »
  9. Vyndaqel (tafamidis) prolongs life of FAP patients

    Positive news for patients with early-stage FAP; results from a Portuguese study show that a liver transplant or Vyndaqel may extend survivability.

    grandfather pointing into sea

    Read more »
  10. A new gene therapy on the horizon for SMA

    Zolgensma (onasemnogene abeparvovec-xxxx) to receive priority review by FDA as a one-time treatment of type 1 spinal muscular atrophy (SMA).

    baby outside reaching toward viewer

    Read more »
  11. Bavencio (avelumab) misses ovarian cancer trial endpoints

    A late-stage study testing Bavencio (avelumab) has failed to meet its primary endpoints in patients with certain forms of ovarian cancer.

    woman backlit sun field

    Read more »
  12. Ocrevus (ocrelizumab) helps preserve hand and arm function in PPMS

    In an exploratory study Ocrevus (ocrelizumab) slowed down loss of function in the upper extremities for patients with primary progressive multiple sclerosis (PPMS).

    woman raised hands near water

    Read more »
  13. Where data and humanity meet: an algorithm to improve medicine pricing models

    Industry NewsHow two professors imagine a better world for stakeholders in the medical industry. 

    Read more »
  14. Mystery around a high-risk leukaemia solved

    "These results offer a leap in understanding about this disease that provides a genetically based framework for designing clinical trials to develop more effective treatments of MPAL," 

    High-Risk Leukaemia

    Read more »
  15. New method promises fewer side effects from cancer drugs

    "In short, it will help produce drugs where we can be far more confident about where modifications are being made, so that side effects can be minimized in the future"

    Fewer Side Effects

    Read more »
Page